Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells

References

• DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409–18
   PubMed Web of Science ®Google Scholar
• Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010;17:173–6
   PubMed Web of Science ®Google Scholar
• Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliver Rev 2010;62:203–30
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Gu FX, Karnik R, Wang AZ, et al. Targeted nanoparticles for cancer therapy. Nano Today 2007;2:14–21
   Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771–82
   PubMed Web of Science ®Google Scholar
• Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002;83:273–86
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505–15
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505–10
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818–22
   PubMed Web of Science ®Google Scholar
• Fang X, Tan, W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Accounts Chem Res 2009;43:48–57
   Web of Science ®Google Scholar
• Orava EW, Cicmil N, Gariepy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 2010;1798:2190–200
   PubMed Web of Science ®Google Scholar
• Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009;86:151–64
   PubMed Web of Science ®Google Scholar
• Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011;32:8010–20
   PubMed Web of Science ®Google Scholar
• Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722–30
   PubMed Web of Science ®Google Scholar
• You K, Niho S, Goto K, et al. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol 2004;34:206–9
   PubMed Web of Science ®Google Scholar
• Zhang HY, Tang X, Li HY, Liu XL. A lipid microsphere vehicle for vinorelbine: stability, safety and pharmacokinetics. Int J Pharm 2008;348:70–9
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Z, Gong W, et al. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate. Int J Pharm 2011;414:56–62
   PubMed Web of Science ®Google Scholar
• You J, Wan F, Cui F, et al. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm 2007;343:270–6
   PubMed Web of Science ®Google Scholar
• Sanna V, Pintus G, Bandiera P, Anedda R. Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents. Mol Pharmaceutics 2011;8:748–57
   PubMed Web of Science ®Google Scholar
• Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007;28:869–76
   PubMed Web of Science ®Google Scholar
• Brody JR, Calhoun ES, Gallmeier E, et al. Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media. Biotechniques 2004;37:598–602
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Rel 2012;161:175–87
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hirano K, Takahashi A, et al. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol Pharm Bull 2010;33:796–803
   Google Scholar
• Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012;33:5115–23
   PubMed Web of Science ®Google Scholar
• Yu C, Hu Y, Duan J, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 2011;6:e24077
   PubMed Web of Science ®Google Scholar
• Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA–PEG nanoparticles. Proc Natl Acad Sci USA 2008;105:17356–61
   PubMed Web of Science ®Google Scholar
• Aravind A, Jeyamohan P, Nair R, et al. AS1411 aptamer tagged PLGAlecithinPEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 2012;109:2920–31
   PubMed Web of Science ®Google Scholar
• Mosqueira VCF, Legrand P, Morgat J, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res 2001;18:1411–19
   PubMed Web of Science ®Google Scholar
• Zhang N, Chittasupho C, Duangrat C, et al. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjugate Chem 2007;19:145–52
   PubMed Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, et al. ‘Stealth'corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surf B 2000;18:301--13
   PubMed Web of Science ®Google Scholar
• Duan Y, Sun X, Gong T, et al. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. J Mater Sci: Mater Med 2006;17:509–16
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006;103:6315–20
   PubMed Web of Science ®Google Scholar
• Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomed-Nanotechnol 2009;5:323–33
   PubMed Web of Science ®Google Scholar
• Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol 2009;76:984–91
   PubMed Web of Science ®Google Scholar